The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line

Purpose: Hepatocellar carcinoma (HCC) remains a major health problem being the third leading cause of deaths due to cancer worldwide. Because HCC is known to be highly resistant to conventional systemic therapies, single-agent or combination of systemic therapies have been investigated Today, sorafenib, a multikinase inhibitor, is the only approved systemic agent for the first line treatment of advanced HCC. In this study, we aimed to investigate the influence of different concentrations of cisplatin, doxorubicin, pegylated doxorubicin (PLD), oxaliplatin and gemcitabine by applying these agents either single or in combinations on mahlavu cell line. Methods: HCC mahlavu cell line was used for the experiments. Cell death was measured by flow cytometry at 48 hrs after incubation with various concentrations (0.1 uglml, 1.0 uglml and 10 uglml) of the drugs. Results: Cell death due to gemcitabine was found to be significantly higher than cell deaths caused by the other single agents including cisplatin, oxaliplatin, doxorubicin and PLD (p<0.001, p<0.001, p<0.001 and p=0.0049, respectively). There was no significant difference between gemcitabine and both the gemcitabine combination with doxorubicin and PLD (p=0.992 and p=0.441, respectively). Conclusion: This is a preliminary analysis evaluating the effect of the conventional chemotherapeutic agents on mahlavu cell line in vitro. The findings of this study suggest that gemcitabine-based therapies keep on being the prefered therapeutic approach for the treatment of HCC.

Dergi Adı Journal of B.U.ON.
Dergi Cilt Bilgisi 20
Dergi Sayısı 2
Sayfalar 608 - 613
Yayın Yılı 2015
Eser Adı
[dc.title]
The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line
Yazar
[dc.contributor.author]
Ilikhan S.U.
Yazar
[dc.contributor.author]
Bilici M.
Yazar
[dc.contributor.author]
Sahin H.
Yazar
[dc.contributor.author]
Akca A.S.D.
Yazar
[dc.contributor.author]
Engin H.
Yazar
[dc.contributor.author]
Bilir C.
Yazar
[dc.contributor.author]
Sevinc N.
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
Zerbinis Publications
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose: Hepatocellar carcinoma (HCC) remains a major health problem being the third leading cause of deaths due to cancer worldwide. Because HCC is known to be highly resistant to conventional systemic therapies, single-agent or combination of systemic therapies have been investigated Today, sorafenib, a multikinase inhibitor, is the only approved systemic agent for the first line treatment of advanced HCC. In this study, we aimed to investigate the influence of different concentrations of cisplatin, doxorubicin, pegylated doxorubicin (PLD), oxaliplatin and gemcitabine by applying these agents either single or in combinations on mahlavu cell line. Methods: HCC mahlavu cell line was used for the experiments. Cell death was measured by flow cytometry at 48 hrs after incubation with various concentrations (0.1 uglml, 1.0 uglml and 10 uglml) of the drugs. Results: Cell death due to gemcitabine was found to be significantly higher than cell deaths caused by the other single agents including cisplatin, oxaliplatin, doxorubicin and PLD (p<0.001, p<0.001, p<0.001 and p=0.0049, respectively). There was no significant difference between gemcitabine and both the gemcitabine combination with doxorubicin and PLD (p=0.992 and p=0.441, respectively). Conclusion: This is a preliminary analysis evaluating the effect of the conventional chemotherapeutic agents on mahlavu cell line in vitro. The findings of this study suggest that gemcitabine-based therapies keep on being the prefered therapeutic approach for the treatment of HCC.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Cell death
Konu Başlıkları
[dc.subject]
Chemotherapy
Konu Başlıkları
[dc.subject]
Hepatocellular carcinoma
Konu Başlıkları
[dc.subject]
Mahlavu cell line
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1107-0625
İlk Sayfa Sayısı
[dc.identifier.startpage]
608
Son Sayfa Sayısı
[dc.identifier.endpage]
613
Dergi Adı
[dc.relation.journal]
Journal of B.U.ON.
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
20
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/8129
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
22
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
17 Haziran 2024 11:06
Google Kontrol
Tıklayınız
doxorubicin gemcitabine mahlavu therapies systemic agents treatment respectively) concentrations cisplatin oxaliplatin single combination deaths conventional higher significantly findings various Results prefered approach gemcitabine-based therapeutic uglml) suggest chemotherapeutic difference significant incubation Conclusion between preliminary including analysis
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms